SB271046 5-HT6 receptor antagonist orally active SB-271046 CAS: 209481-20-9

CAS NO: 209481-20-9
SB271046 5-HT6 receptor antagonist orally active SB-271046
Chemical Name: SB271046
Molecular Formula: C20H22ClN3O3S2
Formula Weight: 451.99
CAS No.: 209481-20-9
Description Review
Description

SB271046 is a selective antagonist of the 5-HT6 receptor, a type of serotonin receptor that is primarily expressed in the brain. In this article, we will delve into the chemical properties of SB271046, its health benefits, potential effects, mechanism of action, possible side effects, and dosing information.

Chemical Properties

The chemical name of SB271046 is (R)-3-(2-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethyl)-1H-indole. Its molecular formula is C21H21NO2O2 and formula weight is 335.40 g/mol. The CAS number of SB271046 is 209481-20-9.

Top Ten Keywords and Synonyms

  1. 5-HT6 receptor antagonist
  2. SB271046
  3. Cognitive enhancement
  4. Schizophrenia treatment
  5. Depression therapy
  6. Serotonin receptor
  7. Neurotransmitter
  8. Mood disorders
  9. Memory improvement
  10. Alzheimer's disease

Synonyms:

  1. SB271046
  2. (R)-3-(2-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethyl)-1H-indole

Health Benefits

SB271046 has shown potential benefits in treating cognitive impairment associated with various neurological disorders such as schizophrenia, depression, and Alzheimer's disease. It may also have applications in enhancing memory and cognition in healthy individuals.

Potential Effects

SB271046 primarily acts as an antagonist of the 5-HT6 receptor, which is involved in regulating the release of neurotransmitters such as dopamine, serotonin, and acetylcholine. By blocking the 5-HT6 receptor, SB271046 can enhance the release of these neurotransmitters, which may improve cognitive function, mood, and memory.

Product Mechanism

The 5-HT6 receptor is a G-protein-coupled receptor that modulates the release of various neurotransmitters in the brain. SB271046 selectively blocks the binding of serotonin to the 5-HT6 receptor, thereby reducing its downstream signaling pathways. This ultimately enhances the release of other neurotransmitters and improves cognitive function and memory.

Safety

SB271046 has demonstrated a good safety profile in preclinical studies. However, there is limited information on its safety in humans, and further research is needed to determine its long-term safety and potential toxicities.

Side Effects

There is limited information on the side effects of SB271046 in humans. In animal studies, SB271046 has been shown to cause sedation and impair motor function, but these effects are generally mild and reversible.

Dosing Information

SB271046 has been administered orally in preclinical studies at doses ranging from 0.1 to 30 mg/kg. The optimal dose and duration of treatment for various neurological disorders are unknown, and further research is needed to establish safe and effective dosing regimens.

Conclusion

SB271046 is a promising 5-HT6 receptor antagonist with potential therapeutic applications in cognitive impairment associated with various neurological disorders such as schizophrenia, depression, and Alzheimer's disease. Its mechanism of action involves enhancing the release of neurotransmitters such as dopamine, serotonin, and acetylcholine, which may improve cognitive function, mood, and memory. While it has demonstrated a good safety profile in preclinical studies, more research is needed to determine its long-term safety and potential side effects in humans. Nonetheless, SB271046 has great potential as a novel therapeutic agent in the treatment of various neurological disorders.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us